NASDAQ · TECX
Tectonic Therapeutic, Inc.
$20.50-$0.06 (-0.29%)
Tectonic Therapeutic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.14% below the high.
Loading market information…
NASDAQ · FRTX · USD
Stock price, earnings
Quote as of Feb 28, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Fresh Tracks Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Fresh Tracks Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:10 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 12, 2022 |
| -$3.60-39.0% vs estimate |
| $92.00K0.0% vs estimate |
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$20.50-$0.06 (-0.29%)
Tectonic Therapeutic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.14% below the high.
$3.06-$0.30 (-8.93%)
Neuphoria Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.67% below the high.
$2.85-$0.15 (-5.0%)
Entero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.2% below the high.
$5.20+$1.69 (+48.15%)
TNF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.33% below the high.
$0.11$0.00 (0.0%)
Tricida, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.22% below the high.
$2.12+$0.02 (+0.95%)
Xenetic Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.09% below the high.
$1.36+$0.01 (+0.74%)
BiondVax Pharmaceuticals Ltd.’s quoted price sits in the lower half of its reported 52-week range, 88.16% below the high.
$1.71+$1.71 (+100.0%)
Aptose Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.04% below the high.
